Table 4 Average direct costs incurred per low- and high-risk NSI
From: Economic benefits of safety-engineered sharp devices in Belgium - a budget impact model
NSI risk category | Low | High | ||
|---|---|---|---|---|
Source patient | Known | Â | Unknown | Â |
Infection status | Uninfected | Infected | Uninfected | Infected |
Testing | €141.20 | €141.20 | €85.09 | €85.09 |
Staff and administration | €68.81 | €68.81 | €68.81 | €68.81 |
PEP | – | €374.61 | €918.76 | €918.76 |
Disease treatment | – | €142.99 | – | €142.99 |
Total direct cost per NSI | €210.01 | €727.61 | €1,072.66 | €1,215.65 |
Relative incidence within risk category | 100% | 33% | 58% | 10% |
Total direct cost per NSI, by risk category | €210.01 | €950.34 | ||